A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study
- Collignon, A.
- Hospital, M.,
- Montersino, C.
- Courtier, F.
- Charbonnier, A.
- Saillard, C.
- D’incan, E.
- Mohty, B.
- Guille, A.
- Adelaïde, J.
- Carbuccia, N.
- Garnier, S.
- Mozziconacci, M.,
- Zemmour, C.
- Pakradouni, J.
- Restouin, A.
- Castellano, R.
- Chaffanet, M.
- Birnbaum, D.
- Collette, Yves
- Vey, N.
DOIAbstract
International audienceTargeted next-generation sequencing (tNGS) and ex vivo drug sensitivity/resistance profiling (DSRP) have laid foundations defining the functional genomic landscape of acute myeloid leukemia (AML) and premises of personalized medicine to guide treatment options for patients with aggressive and/or chemorefractory hematological malignancies. Here, we have assessed the feasibility of a tailored treatment strategy (TTS) guided by systematic parallel ex vivo DSRP and tNGS for patients with relapsed/refractory AML (number NCT02619071). A TTS issued by an institutional personalized committee could be achieved for 47/55 included patients (85%), 5 based on tNGS only, 6 on DSRP only, while 36 could be proposed on the basis of bot...
Add to ORKG